Certified by Founder Lodge 
                                        
                                        RiverVest Venture Partners
 
                                                 United States  -  St. Louis, MO 
                                             INVESTOR 
                                            
                                                                                    1 Disclosed Funding Rounds $14,000,000
                                            12 Participating Investments
- 
                                                Operating Status 
                                                
Active
 - 
                                                Last Funding Type 
                                                
Seed
 - 
                                                Company Type 
                                                
For Profit
 - Website
 - Contact
 - Social Links
 
                                            RiverVest Venture Partners® is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investo
                                        
                                        
                                        
                                                                                
                                        
                                        
                                        
                                        
                                                                                
                                        | Company | Date | Round | Raised | 
|---|---|---|---|
   Alleviant Medical | 
                                                            January, 16 ,2025 | Unknown | $90,000,000 | 
   OncoResponse | 
                                                            May, 19 ,2023 | Unknown | $14,000,000 | 
   Avalyn Pharma Inc. | 
                                                            September, 28 ,2023 | Series C | $175,000,000 | 
   Atalanta Therapeutics | 
                                                            January, 29 ,2025 | Series B | $75,000,000 | 
   Engrail Therapeutics | 
                                                            March, 20 ,2024 | Series B | $157,000,000 | 
   Glycomine Inc. | 
                                                            April, 17 ,2025 | Series C | $115,000,000 | 
   Bluejay Therapeutics | 
                                                            May, 10 ,2024 | Series C | $182,000,000 | 
   InterVene, Inc. | 
                                                            October, 08 ,2024 | Series A | $13,000,000 | 
   Alleviant Medical | 
                                                            January, 16 ,2025 | Unknown | $90,000,000 | 
   Atalanta Therapeutics | 
                                                            January, 29 ,2025 | Series B | $75,000,000 | 
   Glycomine Inc. | 
                                                            April, 17 ,2025 | Series C | $115,000,000 | 
   Sparrow Pharmaceuticals, Inc. | 
                                                            September, 25 ,2025 | Series B | $95,000,000 | 
                                                
  Alleviant Medical
  OncoResponse
  Avalyn Pharma Inc.
  Atalanta Therapeutics
  Engrail Therapeutics
  Glycomine Inc.
  Bluejay Therapeutics
  InterVene, Inc.
  Sparrow Pharmaceuticals, Inc.
Cherry Ventures
 
                                            
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                                                        
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)